Concepedia

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

Mauricio Pineda‐Roman, Maurizio Zangari, Frits van Rhee, E. Anaissie, Jackie Szymonifka, Antje Hoering, Nathan Petty, John Crowley, John D. Shaughnessy, Joshua Epstein,

Leukemia · 2008 · 139 citations · 37 references

Open access

Concepts

MedicinePharmacologyPharmacotherapyChemotherapyHematologic OncologyImmunotherapyCombination Cancer TherapyCombination ChemotherapyCombination ImmunotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyMultiple MyelomaBortezomib-based RegimensCombination TherapyLenalidomide TherapyMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentRefractory Multiple Myeloma

References

37

Regression Models and Life-Tables

D. R. Cox · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1972 · 39.3K citations · Full text

Public Health, Biostatistics, Hazard Identification +16

Nonparametric Estimation from Incomplete Observations

Edward L. Kaplan, Paul Meier · Journal of the American Statistical Association · 1958 · 39.1K citations

Public Health, Biostatistics, Mathematics +10

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Seema Singhal, Jayesh Mehta, Raman Desikan et al. · New England Journal of Medicine · 1999 · 2.6K citations · Full text

Medicine, Hematology, Oncology +14

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14